Ditiotreitol-behandling av erytrocyter vid förenlighetsprövning av blod till patienter med Darzalex medicinering

Ditiotreitol-behandling av erytrocyter vid förenlighetsprövning av blod till patienter med Darzalex medicinering

Introduktion: Daratumumab är en monoklonal antikropp som används för att behandla patienter med multipelt myelom (MM), en typ av blodcancer som har sitt ursprung i B-lymfocyter. Daratumumab binder till CD38 som normalt uttrycks på erytrocyternas yta och ger upphov till panreaktivitet vid förenlighet...

Full description

Bibliographic Details
Main Author:	Ghilai, Merry
Format:	Others
Language:	Swedish
Published:	Örebro universitet, Institutionen för hälsovetenskaper 2021
Subjects:	Daratumumab dithiothreitol CD38 panaaglutination RBC-reagents ditiotreitol panreaktivitet testerytrocyter Biomedical Laboratory Science/Technology Biomedicinsk laboratorievetenskap/teknologi
Online Access:	http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-92904

Similar Items

Interference of daratumumab with compatibility testing in blood bank
by: Rani Premkumar, et al.
Published: (2019-01-01)

Daratumumab interference with immunohematology testing in a nonmultiple myeloma neutropenic patient, in need of granulocyte transfusion
by: Abhaykumar Malind Gupta, et al.
Published: (2021-01-01)

Verifiering av metod för dithiothreitolbehandling av testerytrocyter
by: Gustafsson, Jonna
Published: (2020)

Resolving crossmatch incompatibility due to daratumumab in multiple myeloma
by: S Anuragaa, et al.
Published: (2020-01-01)

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
by: Huiqiang Huang, et al.
Published: (2021-02-01)

Daratumumab (Anti-CD38) interference with serological testing: An emerging challenge for blood banks in developing countries
by: Rasika Setia, et al.
Published: (2017-01-01)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
by: Soma Agrawal, et al.
Published: (2020-01-01)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)

Daratumumab for the Treatment of Multiple Myeloma
by: Torben Plesner, et al.
Published: (2018-06-01)

The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
by: Eleonora Calabretta, et al.
Published: (2020-03-01)

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
by: Guido Lancman, et al.
Published: (2018-11-01)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
by: Dario Roccatello, et al.
Published: (2020-06-01)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
by: Tao Yu, et al.
Published: (2019-05-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
by: Alberto L. Horenstein, et al.
Published: (2015-09-01)

Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome
by: Daniel E. Pleguezuelo, et al.
Published: (2021-04-01)

Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis
by: Gregory P. Kaufman, et al.
Published: (2021-02-01)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
by: Niels W.C.J. van de Donk, et al.
Published: (2018-09-01)

Resistance Mechanisms Towards CD38−Directed Antibody Therapy in Multiple Myeloma
by: Laurens E. Franssen, et al.
Published: (2020-04-01)

Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
by: Hana Vakili, et al.
Published: (2020-04-01)

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
by: Suzanne Cole, et al.
Published: (2018-05-01)

HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
by: Nizar Joher, et al.
Published: (2021-05-01)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
by: McEllistrim C, et al.
Published: (2017-04-01)

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE
by: Morgane Humbel, et al.
Published: (2021-03-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab
by: Lei Kang, et al.
Published: (2021-05-01)

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease
by: Anna Zaninoni, et al.
Published: (2021-03-01)

Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells
by: M. Tommy Gambles, et al.
Published: (2021-07-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
by: Xun Ma, et al.
Published: (2018-10-01)

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
by: Jayeeta Ghose, et al.
Published: (2018-10-01)

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
by: Maria C. Ochoa, et al.
Published: (2019-07-01)

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
by: Hanley N. Abramson
Published: (2018-12-01)

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab
by: Nedumcheril MT, et al.
Published: (2021-05-01)

Daratumumab efficacy in extramedullary orbital myeloma
by: Alessandro Gozzetti, et al.
Published: (2020-12-01)

Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
by: Dario Roccatello, et al.
Published: (2020-10-01)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
by: Francesca Cottini, et al.
Published: (2021-02-01)

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody
by: Mei-Hwa Lin, et al.
Published: (2017-01-01)

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
by: Serika D Naicker, et al.
Published: (2021-01-01)